{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-26-000055","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2026-08-13T20:06:49+00:00","discovered_at":"2026-08-13T20:09:04.456747+00:00","generated_at":"2026-08-13T20:09:27.087896+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elicio Q2 net loss $8.2M; Phase 2 AMPLIFY-7P trial misses primary endpoint","bullets":["Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS pancreatic cancer did not meet primary endpoint; evaluating R0 resected subgroup for Phase 3 strategy.","Q2 2026 net loss $8.2M ($0.43/share) vs $10.6M ($0.66/share) in Q2 2025; R&D expense $6.8M, G&A $3.6M.","Cash $23.5M at June 30, 2026; July 2026 $15.0M registered direct offering; runway into Q1 2027.","Plans Phase 1 combo study of ELI-002 7P + RAS inhibitor ± anti-PD-1 in metastatic pancreatic cancer, Q4 2026; multiple complete responses observed.","MSK-led Phase 1 neoadjuvant trial of ELI-002 7P + chemo + checkpoint inhibition activated."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-26-000055","json":"https://secwatch.observer/filing/0001601485-26-000055.json","markdown":"https://secwatch.observer/filing/0001601485-26-000055.md","text":"https://secwatch.observer/filing/0001601485-26-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/0001601485-26-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:09:27.087896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}